TECENTRIQ + AVASTIN + CARBOPLATIN/PACLITAXEL is approved in 1L mNSCLC

TECENTRIQ® + AVASTIN® + CARBOPLATIN/PACLITAXEL TECENTRIQ combination* is now approved for 1L metastatic non-squamous non-small cell lung cancer (mNSCLC) Dear Colleagues, TECENTRIQ, in combination with Avastin (bevacizumab) and carboplatin/paclitaxel (carbo/pac) is a new regimen indicated for 1L treatment of mNSCLC. TECENTRIQ combination* is the first cancer immunotherapy to demonstrate meaningful OS advantage in EGFR/ALK+ who have previously progressed on tyrosine kinase inhibitors (TKIs) as well as in patients with liver metastases (mets). The efficacy and safety of TECENTRIQ combination* was established in the IMpower150 clinical trial. IMpower150 A phase III multicentre, international, randomised, open-label, 3-arm trial in mNSCLC (N=1,202) comparing TECENTRIQ+Avastin+carbo/pac vs Avastin+carbo/pac alone. LEARN MORE TECENTRIQ combination*: delivered a statistically significant OS benefit vs Avastin + carbo/pac alone HR= Hazard ratio CI = Confidence interval PFS at 12 months was nearly doubled in TECENTRIQ combination* vs Avastin+carbo/pac alone (38% vs 20%, HR= 0.59;95% CI, 0.69; P<0.0001). TECENTRIQ combination* is the first cancer immunotherapy combination to demonstrate clinically meaningful survival in EGFR/ALK+ who have progressed on TKIs as well as in patients with liver mets. Median OS (95% CI, 0.29, 1.03) was NR in TECENTRIQ combination* vs 17.5 months in Avastin + carbo/pac. Median OS (95% CI, 0.33, 0.82) in liver mets was 13.3 months versus 9.4 months in Avastin + carbo/pac. HR= Hazard ratio A majority of patients responded to TECENTRIQ combination* vs Avastin+carbo/pac alone HR= Hazard ratio CI = Confidence interval ORR was 56.4% (95% CI, 51.4, 61.4) with TECENTRIQ combination* vs 40.2% (95% CI, 35.3, 45.2) with Avastin+carbo/pac. SEE CLINICAL TRIAL DATA VIDEO During ESMO 2018, Prof. Martin Reck, MD, PhD (Principal investigator of the IMpower150 trial) from Grosshansdorf Lung Clinic, Grosshansdorf, Germany provided a summary of the trial design and its key results. This video has been produced and funded by VJ Oncology. F. Hoffmann-La Roche Ltd did not participate in the filming or editing of this video. The video reflects independent opinions of the speaker. Test your knowledge on TECENTRIQ and cancer immunotherapy Take the quiz and find out how much you know about TECENTRIQ clinical trials and cancer immunotherapy START THE QUIZ References 1. TECENTRIQ Summary of Product Characteristics. Roche. March 2019.  * TECENTRIQ combination = TECENTRIQ + Avastin (bevacizumab) + carboplatin/paclitaxel ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Reporting suspected adverse events or reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse events or reactions Full prescribing information available. Download the EU TECENTRIQ SmPC  here. @ 2019 F. Hoffmann-La Roche Ltd.